论文部分内容阅读
新药时代,造血干细胞移植在多发性骨髓瘤(MM)综合治疗中的地位受到挑战。一些大规模、多中心、前瞻性的临床研究结果显示,对于年轻,具有遗传学高危因素,且有合适供者的MM患者,应首选异基因造血干细胞移植。对于不能接受异基因造血干细胞移植的患者,自体移植同样可以改善患者预后,延长患者生存期。因此,在新药时代,合理综合地运用新药与造血干细胞移植治疗,将会使患者最大程度获益。
In the new drug era, the status of hematopoietic stem cell transplantation in the treatment of multiple myeloma (MM) is challenged. A number of large, multicenter, prospective clinical studies have shown that allogeneic hematopoietic stem cell transplantation should be the first choice for young MM patients with high risk of genetics who have a suitable donor. For patients who can not accept allogeneic hematopoietic stem cell transplantation, autologous transplantation can also improve patient outcomes and prolong patient survival. Therefore, in the new drug era, rational and comprehensive use of new drugs and hematopoietic stem cell transplantation will benefit the patients to the maximum extent.